Venture Capital 2026

Last Updated May 12, 2026

China

Law and Practice

Authors



Zhong Lun Law Firm was established in 1993, and is a pioneering partnership law firm in China. Through decades of strategic growth and unwavering commitment to excellence, the firm has emerged as a pre-eminent full-service law firm. With nearly 400 equity partners and a robust team of over 2,200 professionals, Zhong Lun represents the pinnacle of legal expertise and institutional capability. As one of the first Chinese law firms to specialise in private equity, Zhong Lun has developed unparalleled insights and deep-rooted expertise in this complex domain. Its practice comprehensively addresses the entire life cycle of private fund operations. By combining meticulous legal acumen with strategic foresight, the firm has consistently positioned itself as a leading legal service provider in China’s dynamic private equity landscape. Its sustained excellence has been internationally recognised, with Chambers Global repeatedly ranking Zhong Lun in Band 1 for Private Equity – a testament to the firm’s exceptional performance and industry leadership.

China’s Growth Companies Market: Divergence From Global Recovery Trends

China’s venture capital (VC) market for growth companies demonstrated tentative stabilisation throughout 2025 and into early 2026, yet this recovery has diverged significantly from global trends. While international markets – particularly in the United States and Europe – experienced robust VC rebound through 2024–2025, China’s market recovery remained constrained by structural factors including persistent IPO bottlenecks, geopolitical tensions affecting cross-border capital flows, and evolving regulatory frameworks. Fundraising conditions remained challenging for Mainland China-focused private equity (PE) and VC funds through late 2025, contrasting sharply with the capital-raising momentum observed in Western markets.

LaNova Medicines: Financial Investor Windfall Through Strategic M&A

The July 2025 acquisition of LaNova Medicines by Hong Kong-listed Sino Biopharmaceutical exemplifies the strategic M&A exit route that has emerged as a premier liquidity mechanism for life sciences PE/VC investors in China’s evolving market landscape. The transaction valued LaNova at approximately USD951 million, representing one of the largest pharmaceutical deals in the Asia-Pacific region in 2025 and delivering exceptional returns to financial investors amidst challenging market conditions.

Transaction structure and value creation

LaNova had raised approximately USD200 million through multiple funding rounds from PE/VC investors. The USD951 million acquisition (approximately USD500.9 million net of cash) represented a substantial multiple on invested capital, achieved within a relatively compressed timeframe despite the broader biotech sector’s valuation pressures through 2024–2025. Sino Biopharmaceutical acquired 100% of LaNova (having previously held 4.91% from November 2024), enabling complete portfolio exits for financial investors.

Strategic licensing as a driver of value

Financial investors benefited enormously from LaNova’s strategic licensing deals with Western pharmaceutical giants, which de-risked the technology platform and validated commercial potential well before exit. AstraZeneca licensed LM-305, a G-protein targeting antibody-drug conjugate (ADC), in 2023. More significantly, Merck & Co secured global rights to LM-299, an anti-PD-1/VEGF bispecific antibody, in 2024. These licensing transactions transformed LaNova from a clinical-stage biotech into a proven innovation platform with blue-chip validation, directly driving the acquisition’s near-billion-dollar valuation despite the absence of marketed products.

M&A Advantages Over Traditional Exit Routes

The strategic acquisition route provided PE/VC investors with several critical advantages over alternative exit paths.

Certainty and speed

The transaction closed within approximately 30 business days from announcement, providing liquidity far faster than the protracted IPO approval process that stalled numerous biotech listings through 2025.

Full liquidity

The 100% acquisition structure enabled complete portfolio exits without the lock-up periods, share reduction restrictions and market liquidity constraints that characterise post-IPO exits in both A-share and Hong Kong markets.

Valuation protection

The negotiated acquisition price protected investors from the valuation volatility and post-IPO price declines that plagued biotech public offerings through 2024–2025.

Regulatory simplicity

Unlike IPO exits requiring China Securities Regulatory Commission (CSRC) filing notices, extended reviews and ongoing public company compliance, the M&A transaction required only standard merger control and foreign investment approvals.

Strategic Buyer Rationale and Market Implications

Sino Biopharmaceutical’s acquisition was driven by the desire to strengthen research and development (R&D) capabilities and enhance competitiveness in oncology – precisely the type of strategic rationale that supports premium valuations. LaNova’s robust pipeline (two registration-stage projects, six Phase I/II trials and over ten preclinical programmes) and proven platform technology justified the substantial valuation.

Key Investment Lessons

The LaNova transaction reinforces several strategic lessons for PE/VC investors in Chinese life sciences companies.

  • Early-stage licensing partnerships with multinational pharmaceutical companies serve dual purposes: they provide validation and non-dilutive capital while creating option value that strategic acquirers will pay premiums to control.
  • Platform technology companies with multiple pipeline assets command significantly higher M&A valuations than single-asset biotechs, even in clinical stages.
  • Strategic M&A exits can deliver superior risk-adjusted returns compared to IPO routes, particularly when licensing deals have already established fair market valuation benchmarks.
  • Chinese biotech assets remain highly attractive to domestic strategic acquirers despite broader market headwinds, as companies such as Sino Biopharmaceutical pursue innovation-driven growth strategies.

This transaction demonstrates that, despite challenging market conditions, well-positioned portfolio companies with validated technology platforms and strong pipelines can achieve substantial exits that deliver exceptional returns to financial investors. The momentum that built through 2025 suggests M&A will likely remain the primary exit route for PE/VC investors in the absence of significant changes to the IPO approval environment.

Market Dynamics and Contraction

2025–2026 market stabilisation and bifurcation

China’s PE/VC sector demonstrated tentative recovery throughout 2025 and into early 2026, characterised by uneven progress across exit channels. Exit activity improved selectively, with recovery concentrated in strategic M&A sales and Hong Kong listings rather than broad-based public market exits. M&A transactions gained significant momentum, supported by regulatory reforms and investor pragmatism in response to persistent IPO constraints.

By early 2026, a bifurcated exit landscape has become entrenched: M&A transactions and Hong Kong listings continue gaining traction while A-share IPOs remain structurally constrained. This dynamic has forced funds to maintain recalibrated exit expectations and extended portfolio timelines.

Fundraising conditions remain challenging for Mainland China-focused PE and VC funds. However, strategic domestic investments have driven M&A transaction value growth, with first-half 2025 figures showing a 45% year-over-year surge in deal value, demonstrating resilient domestic strategic buyer appetite despite broader market headwinds.

Geopolitical decoupling: escalating USA–China investment controls

USA–China geopolitical tensions have intensified significantly through 2025 and into 2026, fundamentally reshaping cross-border investment flows and compliance obligations.

Market impact

US-origin capital flows into Chinese technology sectors continued declining through 2025 and into early 2026. Major global firms maintain strict operational and governance firewalls between China and non-China platforms following earlier structural separations. Chinese companies and their investors now face dual compliance challenges – satisfying both China’s data localisation and cybersecurity requirements and US national security mandates – significantly increasing transaction complexity and compliance costs as we progress through 2026.

Redemption Rights in Chinese PE/VC Transactions: a Deep Dive

Prevalence and structural uniqueness

The Chinese PE/VC landscape exhibits distinctive characteristics in its approach to redemption rights, with over 90% of transactions incorporating these provisions. Notably, approximately two thirds of these arrangements extend to include joint and personal founder liability, functioning essentially as a “put option” – a framework that fundamentally diverges from traditional investment protection mechanisms observed in US or EU markets.

The structural architecture of these rights places significant responsibility on founders, who bear personal liability for investment repayment. Redemption triggers are typically anchored to specific performance metrics, including failure to achieve IPO objectives, missed valuation targets, or shortfalls in predetermined financial benchmarks.

Founder vulnerability: systemic risks

The implications of these structures manifest in profound legal and financial consequences, with over 90% of redemption right cases encompassing both corporate and individual founder liability. The potential ramifications extend beyond mere financial penalties, to include:

  • comprehensive asset seizures;
  • nationwide travel restrictions;
  • inclusion in national credit blacklists; and
  • effective prohibition from future entrepreneurial pursuits.

This vulnerability is further amplified by China’s unique legal framework, characterised by the absence of personal bankruptcy laws and debt discharge mechanisms, resulting in perpetual personal liability for investment shortfalls.

Supreme Court judge interpretation: redemption right exercise parameters, December 2025

In December 2025, a Supreme People’s Court justice publicly stated that, where PE/VC agreements do not specify an exercise period for redemption rights or put options, the “reasonable period” should generally be six months from the triggering event, after which the right may be deemed waived.

This position echoed earlier commentary in the People’s Court Daily but stopped short of a formal judicial interpretation. The guidance triggered intense debate that continues into early 2026. Supporters argue that it enhances transactional certainty and corporate stability; critics warn that it could incentivise premature redemptions, exacerbating liquidity stress at portfolio companies.

2026 update: ongoing judicial uncertainty

Despite the December 2025 Supreme People’s Court justice commentary, judicial practice remains inconsistent as we move through early 2026. Notably, a Beijing court decision in 2025 explicitly declined to adopt the six-month rule, emphasising that such commentary does not constitute binding law. This creates ongoing uncertainty for market participants regarding practical enforceability and timing requirements for redemption rights.

In response, investors are increasingly adopting precise contractual drafting to define specific trigger events with objective criteria, detailed notice procedures and timelines, explicit exercise periods, and clear consequences for failure to exercise within specified periods. This trend towards more detailed redemption provisions continues accelerating through 2026 as market participants seek contractual clarity in the absence of definitive judicial guidance.

Technology, Media and Telecommunications (TMT)

The TMT sector has demonstrated remarkable resilience and strategic significance, particularly in semiconductors, AI and fintech, where investment activity exhibited substantial momentum. This growth trajectory was carefully modulated by regulatory oversight that struck a balance between fostering technological innovation and implementing robust data security protocols, most notably through China’s Data Security Law.

’Despite geopolitical headwinds, technology investment rebounded through 2025 and into 2026. President Xi’s 2026 New Year address highlighted that AI large models accelerated rapidly and domestically developed chips achieved new breakthroughs in 2025, reinforcing continued policy support for hard technology sectors.

China announced large-scale semiconductor and AI funding initiatives throughout 2025, with the National AI Industry Investment Fund launched in January 2025 at USD8.2 billion representing just one component of broader strategic investment estimated at tens of billions of US dollars. Despite US restrictions, China’s semiconductor firms posted substantial profit growth in 2025 amidst the AI boom and tech self-reliance drive, with momentum expected to continue through 2026.

Life Sciences and Biotech

The life sciences and biotechnology sector continued attracting capital through 2025 and into 2026 due to streamlined regulatory pathways, policy prioritisation and a dramatic global biotech resurgence. This sector has benefited from a global pharmaceutical M&A surge, with deal values climbing substantially as Big Pharma confronted a looming USD170 billion patent cliff.

Global biotech equities posted their strongest performance since the COVID-19 pandemic through 2025, while PE capital returned to the sector after a prolonged funding chill. The sector has demonstrated notable structural creativity, with innovative “newco” models gaining traction – arrangements combining licensing agreements with equity stakes in newly formed entities, allowing pharmaceutical companies and biotech investors to share risk while maintaining flexibility around asset development and commercialisation.

This global momentum – driven by surging business development deals, creative deal structures, reviving secondary markets and renewed PE deployment – creates premium exit opportunities for Chinese biotech investors through both strategic acquisitions and international capital markets. Life sciences has emerged as one of the few sectors where Chinese PE/VC can access both domestic and cross-border liquidity despite broader geopolitical constraints, positioning it favourably for continued investment through 2026.

VC Fund Structures in China: a Comprehensive Analysis

Legal framework and organisational structure

The limited partnership enterprise (LPE) dominates China’s VC landscape, featuring a dual-tier management structure. General partners (GPs) serve as strategic architects, bringing expertise from elite consulting firms and entrepreneurial backgrounds, while bearing unlimited personal liability. Limited partners (LPs), comprising institutional investors, state-owned funds and international pension funds, provide capital while maintaining limited liability protection.

Alternative frameworks include Asset Management Association of China (AMAC)-regulated PE funds offering standardised compliance mechanisms, and contractual investment structures allowing greater operational flexibility. These frameworks reflect China’s evolving financial governance landscape.

Governance and decision-making mechanisms

Investment governance centres on GPs as strategic operators, supported by Investment Committees comprising seasoned professionals and industry experts. This structure ensures multi-layered investment scrutiny and comprehensive risk assessment. LPs maintain strategic oversight through carefully negotiated veto rights on fundamental fund matters, including strategy shifts and GP replacement considerations.

Corporate documentation framework

The governance architecture rests on four key documents:

  • the Limited Partnership Agreement (LPA), serving as the constitutional document;
  • Subscription Agreements, governing capital commitments;
  • Private Placement Memorandums (PPMs), detailing investment thesis and risk frameworks; and
  • Side Letters, enabling bespoke arrangements with sophisticated investors.

Ecosystem participants and market context

The ecosystem comprises GPs from elite professional backgrounds, diverse LP constituencies, and custodian banks providing critical infrastructure. Recent trends indicate increasing regulatory sophistication, enhanced transparency requirements and growing institutional participation, reflecting China’s integration with global financial standards.

This sophisticated VC framework balances operational flexibility with strategic governance, establishing a robust foundation for China’s evolving investment landscape.

Primary Economic Participation Mechanisms

Management fee structure

Fund operations are sustained through a standard 2% annual management fee, calculated on committed capital during the investment period and deployed capital during the harvest phase. This structure ensures operational sustainability while providing base compensation for fund principals and covering essential management costs.

Carried interest framework

The carried interest mechanism allocates 20% of fund profits to fund principals, subject to an 8% hurdle rate. This performance-based compensation activates only after LPs recover their initial investment, creating a strong alignment of interests between fund managers and investors.

Market standard terms

Investor protection mechanisms include an 8% preferred return requirement and comprehensive claw-back provisions, enabling recovery of excess carried interest distributions. The governance framework implements high water mark principles to prevent carried interest on unrealised gains, while requiring significant personal capital commitment (1%–5%) from the management team. This economic structure creates a balanced ecosystem that aligns manager incentives with investor interests while maintaining robust protective mechanisms for all stakeholders.

Regulatory Framework for Chinese VC

Securities investment fund law

The foundational regulatory framework establishes comprehensive guidelines for fund establishment, operations and investor protection. This legislation defines permissible investment strategies, risk management protocols and fundamental legal infrastructure, ensuring systematic oversight of investment activities.

AMAC regulations

The Asset Management Association of China (AMAC) mandates compulsory registration and compliance for all VC funds. Requirements encompass detailed information submission, ongoing reporting obligations and periodic regulatory reviews. This framework standardises industry practices while implementing robust monitoring mechanisms for investor protection.

Foreign exchange regulations

The State Administration of Foreign Exchange (SAFE) oversees a specialised framework for funds involving foreign LPs or cross-border investments. The system manages capital contribution restrictions, investment return repatriation and currency conversion protocols, reflecting China’s balanced approach to international capital flows while maintaining careful economic oversight.

Evolving Fund Structures in Chinese VC

Government-backed VC funds

Government guidance funds (GGFs) serve as strategic drivers of national innovation, focusing on critical sectors such as semiconductors, AI and clean energy. These funds align with national initiatives such as Made in China 2025 and the Dual Circulation Strategy, significantly influencing private VC investment patterns.

Impact funds and ESG integration

The market shows increasing adoption of ESG principles and impact investing, particularly in green technology, healthcare innovation and educational technology. Government support through financial subsidies and regulatory incentives reinforces this trend, emphasising renewable energy and sustainable innovation.

Funds-of-funds (FoFs) and continuation funds

FoFs, predominantly backed by government guidance funds, provide strategic diversification across multiple VC investments. Continuation funds offer innovative life cycle management solutions, extending investment horizons and maximising portfolio returns. This structure supports a growing secondary market for VC fund interests.

Foreign participation and extended holding periods

International engagement operates within a controlled framework through Qualified Foreign Limited Partnership (QFLP) programmes. The ecosystem addresses extended holding periods through innovative approaches, including extended fund durations (12–15 years) and strategic co-investment structures.

Corporate Structure and Ownership

Due diligence begins with thorough shareholder verification, examining registered and beneficial ownership structures, undisclosed equity agreements and preference rights. Corporate governance review encompasses incorporation documents, subsidiary structures and governance mechanisms.

Regulatory and Permits

The process validates business licences, sector-specific compliance and alignment with foreign investment regulations.

Contractual Framework

Critical contract analysis covers material agreements, employment arrangements and financial commitments, including detailed examination of security interests and governmental registrations.

Intellectual Property

Intellectual property (IP) verification focuses on ownership confirmation, registration status and licensing agreements, while implementing comprehensive risk mitigation strategies.

Dispute Management

Litigation assessment examines pending disputes, historical proceedings and compliance with judicial decisions.

ESG and Local Context Considerations

Environmental compliance, labour practices and governance mechanisms undergo systematic evaluation. The process incorporates unique Chinese market characteristics, including guanxi networks and dynamic regulatory environments, while maintaining rigorous verification standards.

Investment Round Timeline and Collaboration Framework

Due diligence timeline structure

Early-stage VC rounds typically conclude within two to four weeks, reflecting simpler corporate structures and streamlined diligence requirements. Late-stage PE rounds extend to four to six weeks, accommodating more complex corporate arrangements and comprehensive stakeholder considerations.

Collaborative legal framework

Investors generally engage shared counsel for comprehensive due diligence, with costs typically reimbursed by the company. This collective approach enhances efficiency while reducing redundant investigations. Each investor may retain separate counsel for term negotiations, enabling protection of specific interests within the collaborative framework.

Stakeholder dynamics

The process balances existing investor insights with new investor perspectives, creating a dynamic ecosystem that preserves historical context while incorporating fresh strategic input. This structure maintains efficient collective progress while protecting every single investor’s interests throughout the financing round.

This balanced approach optimises the investment process through structured collaboration while preserving individual stakeholder protections.

Preferred Equity Structures in Chinese VC

Contractual framework

Given the absence of formal “preferred share” classification under PRC law, investors utilise contractually engineered equity interests to establish preferential rights. This innovative approach mirrors common law preferred share characteristics while accommodating Chinese regulatory requirements.

Key preferential rights

These include:

  • dividend preference;
  • liquidation preference;
  • redemption rights;
  • anti-dilution adjustments;
  • pre-emptive rights;
  • right of first refusal (ROFR);
  • co-sale rights;
  • drag-along rights; and
  • protective provisions (veto rights).

Implementation strategy

The structure balances robust investor protection with operational flexibility, tailoring rights to specific investment stages and company trajectories. This framework demonstrates the sophisticated legal engineering prevalent in Chinese VC, effectively bridging regulatory constraints through contractual innovation. This approach creates a comprehensive preferred equity framework that maintains investor protection while adhering to Chinese legal requirements.

Core Document Framework

This framework encompasses the following.

  • Equity/share subscription/purchase agreement:
    1. investment terms and equity allocation;
    2. closing conditions;
    3. comprehensive representations and warranties; and
    4. indemnification provisions.
  • Shareholders’ agreement:
    1. inter-shareholder relationship governance;
    2. investor rights and protections;
    3. exit mechanisms and transfer restrictions; and
    4. corporate governance framework.
  • Articles of association:
    1. fundamental corporate governance structure;
    2. internal operational rules; and
    3. a legally registered constitutional document.

Template Ecosystem

Unlike the standardised National Venture Capital Association (NVCA) framework, Chinese VC relies on proprietary law firm templates. While maintaining consistent structural approaches across funds, these templates allow significant customisation for specific transactions. The ecosystem facilitates template sharing and adaptation while reflecting evolving market practices.

Documentation Strategy

Law firms maintain comprehensive template libraries serving as negotiation starting points. This approach enables sophisticated investment structures while preserving flexibility for unique circumstances, creating a balanced framework that supports efficient deal execution while accommodating transaction-specific requirements.

Liquidation Preference Structure

Seniority frameworks establish hierarchical distribution rights based on investment stage and valuation. Recent market trends show increasing adoption of “double dipping” mechanisms, allowing investors to both recover initial investment with interest and participate in remaining distributions rateably, enhancing downside protection and upside gains.

Anti-Dilution and Pre-Emptive Rights

Anti-dilution protection primarily utilises the Weighted Average Method, adjusting investor ownership based on subsequent financing amounts and pricing. Pre-emptive rights, standard in Chinese VC, enable existing investors to maintain proportional ownership through priority participation in new share issuances.

Redemption Framework

Redemption rights provide strategic exit options through:

  • defined activation timeframes;
  • predetermined redemption pricing;
  • performance-linked triggers; and
  • structured payment mechanisms.

Market Dynamics

The ecosystem demonstrates increasing sophistication in investor protections, particularly in downside scenario provisions. This evolution reflects adaptive responses to changing market conditions and investment risk profiles, creating a more robust protection framework for investors.

As passive shareholders, financial investors commonly rely on pro investor governance mechanisms in venture investments.

Governance Influence Strategies

These include shareholder/board level protective provisions, as follows.

  • Critical corporate matters:
    1. liquidation or dissolution;
    2. a change-of-control deal;
    3. IPO;
    4. related-party transactions;
    5. disposal of major assets;
    6. significant corporate restructuring; and
    7. board composition.
  • Financial matters:
    1. budget approvals;
    2. capital expenditure thresholds;
    3. debt incurrence; and
    4. annual financial plans.
  • Strategic decisions:
    1. material business strategy changes;
    2. M&A;
    3. entry into new business lines; and
    4. significant contractual commitments.

Governance Characteristics

These include a primarily passive investment approach focused on downside protection, indirect management influence, and being structured to prevent value-destructive decisions.

Mechanism of Influence

Contractually defined governance rights are carefully negotiated in shareholders’ agreements, and are balanced to protect investor interests while maintaining management flexibility.

Representations, Warranties and Indemnification

The representations and warranties framework encompasses the following.

  • Corporate fundamentals:
    1. legal establishment and existence;
    2. corporate authorisation validity;
    3. accurate capitalisation structure; and
    4. incorporation compliance.
  • Operational assurances:
    1. financial statement accuracy;
    2. asset ownership verification;
    3. IP rights confirmation; and
    4. material contract validation.
  • Compliance certifications:
    1. regulatory adherence;
    2. employment law compliance;
    3. ESG standard conformity; and
    4. data protection protocols.

Covenant Structure

This encompasses the following.

  • Operational commitments:
    1. ongoing regulatory compliance;
    2. business continuity maintenance; and
    3. asset preservation requirements.
  • Restrictive provisions:
    1. non-compete obligations;
    2. confidentiality requirements; and
    3. corporate change limitations.

Indemnification Framework

This encompasses the following.

  • Compensation scope:
    1. direct financial losses;
    2. equity value diminution; and
    3. transaction-related costs.
  • Liability distribution:
    1. company – primary indemnification responsibility; and
    2. founders – joint liability with cap on their shares’ fair market value/markable value, unless the liability is due to fraud, wilful misconduct or gross negligence, where it is unlimited liability.

This framework establishes comprehensive protection mechanisms while maintaining practical enforceability within the Chinese legal context.

Government Guidance Funds in Chinese Growth Investment

Strategic framework

Government guidance funds represent China’s innovative approach to catalysing strategic investment, combining State direction with market dynamics. These funds strategically mobilise private capital into priority sectors while providing crucial risk mitigation mechanisms, effectively accelerating innovation and supporting economic transformation.

Priority investment sectors

The funds target five key strategic domains that align with China’s long-term development goals:

  • advanced manufacturing – focusing on smart manufacturing, robotics and Industry 4.0 initiatives;
  • clean energy and sustainability – supporting renewable energy, energy storage and green technology;
  • digital economy and AI – advancing cloud computing, big data analytics and AI applications;
  • semiconductor technologies – developing domestic chip design, manufacturing and related equipment; and
  • biotechnology and healthcare – investing in pharmaceutical research, medical devices and healthcare innovation.

Operational structure

The funds operate through a sophisticated investment approach that balances government oversight with market efficiency. This structure employs a private sector co-investment model, typically taking minority equity positions to maintain market dynamics while sharing investment risks. The focus on early-stage funding helps bridge critical financing gaps in emerging sectors.

Investment architecture

The operational framework is built on:

  • multi-tiered investment vehicles that accommodate various risk profiles and investment horizons;
  • professional management teams with both public and private sector expertise;
  • market-driven methodology ensuring commercial viability; and
  • flexible deployment criteria adapting to sector-specific needs.

Corporate Income Tax Structure

China’s corporate tax framework balances standardised taxation with strategic incentives, creating a dynamic environment that supports innovation while maintaining fiscal stability. The system combines broad-based taxation with targeted benefits for strategic sectors and emerging companies.

Standard Tax Regime

The foundation of China’s corporate taxation rests on a universal 25% corporate income tax (CIT) rate, providing a consistent baseline across industries. This standard framework ensures regulatory clarity and establishes a level playing field for all business entities, while serving as the foundation for more specialised provisions.

Innovation Enterprise Benefits

To accelerate technological advancement and economic transformation, qualified innovation-driven enterprises enjoy significant tax advantages:

  • preferential 15% CIT rate – available to companies meeting specific innovation criteria;
  • priority sector focus – technology and AI development, biotechnology research and applications, green energy solutions and advanced manufacturing initiatives; and
  • start-up support – special exemptions for early-stage companies, reducing initial tax burden during critical growth phases.

Investment Vehicle Taxation

The tax treatment of investment vehicles, particularly VC funds, aligns with international best practices while incorporating Chinese characteristics. The framework emphasises:

  • limited partnership structures with tax pass-through benefits;
  • direct taxation at the investor level rather than fund level;
  • mechanisms to prevent double taxation across investment chains; and
  • harmonisation with global investment standards to facilitate cross-border capital flows.

Geographic Tax Incentives

China leverages location-based tax policies to drive regional development and specialised industry clusters.

Strategic zones

Different specialised zones offer distinct advantages:

  • special economic zones – comprehensive tax benefits supporting international trade;
  • high-tech parks – focused incentives for technology development; and
  • free trade zones – enhanced tax provisions for cross-border transactions.

Regional benefits package

Location-specific incentives include:

  • reduced tax rates for qualified operations;
  • strategic tax exemptions for priority industries; and
  • investment subsidies that promote regional development goals.

China’s Equity Financing Ecosystem: Market Evolution Framework

Stock market reform structure

China’s equity market transformation represents a strategic shift towards greater market efficiency and accessibility, fundamentally reshaping the country’s capital raising landscape.

Registration-based IPO system

The transition from an approval-based to a registration-based IPO system marks a significant evolution in China’s capital markets. This modernised approach features:

  • streamlined listing processes, reducing timelines to six months;
  • market-driven valuation mechanisms, replacing administrative pricing;
  • enhanced transparency requirements aligned with international standards; and
  • progressive implementation across STAR Market and ChiNext Board.

Multi-tier market architecture

The ecosystem operates through strategically differentiated boards, each serving distinct company profiles.

  • Main board – home to established corporations with proven track records.
  • SME board – catering to growing mid-sized enterprises with stable operations.
  • ChiNext – platform for high-growth innovative companies.
  • STAR Market – specialised venue for cutting-edge technology firms, focusing on:
    1. semiconductor development and production;
    2. advanced manufacturing technologies; and
    3. AI applications and biotechnology innovations.

International Integration Framework

Cross-border trading mechanisms

China has established robust international market connections through the following.

  • Stock Connect programmes:
    1. Shanghai-Hong Kong connection facilitating northbound/southbound trading;
    2. Shenzhen-Hong Kong link expanding access to tech-focused enterprises; and
    3. Bond Connect initiatives broadening fixed-income market access.
  • QFII/RQFII reforms:
    1. elimination of investment quotas;
    2. simplified application procedures; and
    3. improved market accessibility for global investors.

Global Listing Framework

Companies can optimise their capital-raising through multiple venues:

  • Hong Kong – preferred regional hub offering regulatory familiarity and international exposure;
  • NASDAQ – access to deep technology-focused investor base and global visibility; and
  • alternative platforms – additional options through London and Singapore exchanges.

Global listing strategies prioritise high-growth sectors:

  • technology and AI development;
  • biotechnology innovation;
  • advanced manufacturing capabilities; and
  • digital economy initiatives.

Comprehensive Retention Framework

Chinese venture investments employ a sophisticated combination of legal obligations and incentive structures to ensure long-term commitment from founders and key employees, creating a balanced approach between enforcement and motivation.

Contractual Commitment Mechanisms

Non-compete provisions

The cornerstone of contractual retention includes carefully structured non-compete clauses that extend across multiple timeframes:

  • during the active employment period;
  • throughout the equity ownership duration; and
  • a two-year post-employment restriction period.

Full-time contribution requirements

Comprehensive engagement obligations are structured to ensure dedicated focus and optimal performance. Mandatory engagement elements include:

  • exclusive dedication to the venture’s operations;
  • explicit prohibition of parallel entrepreneurial activities; and
  • specific performance metrics and time commitment standards.

Documentation framework

These obligations are formally documented across multiple agreements:

  • Shareholders’ Agreement (SHA) – governing equity holder obligations;
  • Share Purchase Agreement (SPA) – establishing investment terms; and
  • employment contracts – detailing day-to-day responsibilities.

Breach consequences

The framework includes clear enforcement mechanisms for commitment violations:

  • SPA-triggered indemnity obligations for covenant breaches; and
  • SHA-mandated redemption rights for a material breach.

Additional Retention Strategies

Performance-linked compensation involves a comprehensive incentive structure that complements legal obligations through various mechanisms, as follows.

  • Equity-based incentives:
    1. traditional stock option programmes with vesting schedules;
    2. restricted share units (RSUs) aligned with performance metrics;
    3. phantom equity arrangements for flexible value sharing; and
    4. long-term bonus structures tied to company milestones.
  • Strategic implementation – the compensation framework is designed to:
    1. align individual interests with company success;
    2. create meaningful long-term value potential;
    3. establish clear performance-reward relationships; and
    4. support retention through extended vesting periods.
  • Integration and balance – this multifaceted approach creates a robust retention framework that:
    1. combines protective legal measures with positive incentives;
    2. balances immediate restrictions with long-term rewards;
    3. provides clear consequences while offering growth opportunities; and
    4. maintains flexibility while ensuring commitment.

Equity Retention and Incentive Mechanisms for Founders and Employees

Founder equity framework – restricted share mechanisms

Founder equity retention rests on a sophisticated vesting framework that balances long-term commitment with flexibility.

Vesting structure

  • Time-based vesting:
    1. four-year vesting schedule with one-year cliff;
    2. monthly or quarterly vesting; and
    3. accelerated vesting provisions for qualifying events (M&A/IPO).

Repurchase rights

The company maintains strategic control through carefully structured repurchase provisions.

Trigger events

  • voluntary departure; and
  • termination scenarios (with/without cause).

Valuation framework

  • Unvested shares: repurchase at original cost.
  • Vested shares:
    1. at cost – voluntary departure or for-cause termination; and
    2. fair market value – termination without cause or “good reason”.

Employee equity participation

Employee participation is facilitated through a comprehensive stock option framework:

  • implementation through an LP structure;
  • employee access via LP interests; and
  • five-year standard vesting timeline that promotes long-term alignment.

The framework combines multiple vesting approaches:

  • a time-based vesting schedule; and
  • performance-based acceleration opportunities.

Integration and impact

This comprehensive framework represents a sophisticated approach to equity-based retention and motivation. It effectively balances:

  • short-term performance incentives with long-term value creation;
  • individual reward potential with company risk management; and
  • standardised structures with situation-specific flexibility.

Employee Stock Option Plan (ESOP) Taxation Framework in China – LP ESOP Structure

Tax-efficient configuration

China’s ESOP framework utilises an LP structure that optimises tax efficiency through:

  • transparent tax treatment that enables direct pass-through;
  • elimination of entity-level double taxation;
  • direct attribution of tax obligations to individual participants; and
  • structure alignment with global taxation standards.

Individual income tax assessment

The primary taxable event occurs at option exercise, with careful consideration of the following.

Tax base calculation

Determined by the differential between:

  • current fair market value (FMV) of shares; and
  • original option exercise price.

Progressive tax rate application

  • Rates scale from 3% to 45% based on income levels.
  • Comprehensive income consideration, including:
    1. regular employment income;
    2. option exercise benefits; and
    3. other taxable income sources.

Capital gains taxation

Partnership interest disposal – tax rate structure

  • Standard capital gains rate – 20%.
  • Alternative rate schedule – up to 35%:
    1. applied based on specific circumstances;
    2. consideration of holding periods; and
    3. assessment of disposal volume.

Geographic considerations

Tax obligations vary based on location-specific factors:

  • municipal-level regulations;
  • economic development zone benefits; and
  • special economic region provisions.

Strategic tax planning

Effective ESOP implementation requires careful consideration of:

  • optimal exercise timing;
  • strategic disposal planning;
  • geographic tax arbitrage opportunities; and
  • available tax relief mechanisms.

Documentation requirements

Proper tax treatment depends on maintaining:

  • detailed exercise records;
  • FMV assessments;
  • holding period documentation; and
  • disposal transaction records.

Geographic benefits

Various locations offer distinct advantages:

  • economic development zones providing preferential rates;
  • special economic regions with tax incentives; and
  • municipal-level tax benefits for qualifying transactions.

Timing strategies

Tax efficiency can be enhanced through:

  • strategic exercise timing;
  • planned disposal schedules;
  • co-ordination with other income sources; and
  • utilisation of tax assessment periods.

ESOP and Equity Framework for Chinese Companies – Core Structure and Implementation

Equity pool configuration

A standard allocation range of 10%–20% of total equity applies:

  • implemented through an LP structure with tax pass-through mechanisms;
  • featuring flexible sizing based on company stage, industry characteristics and talent strategy requirements; and
  • supported by systematic dilution management across funding rounds.

Stage-Specific Implementation

Early stage (Seed/Series A)

This involves an initial pool of 10%–15% of total equity with broader distribution patterns focused on early team building, featuring generous individual allocations to attract key talent, and supported by flexible grant structures that enable rapid team expansion and critical role fulfilment.

Growth stage (Series B/C)

This involves dynamic pool adjustments with refined allocation strategy, incorporating performance-linked grants and sophisticated vesting mechanisms, balanced with proportional dilution management and strategic pool replenishment to maintain incentive effectiveness.

Late stage (pre-IPO)

This involves conservative new allocations emphasising retention through sophisticated vesting mechanisms, minimal dilution impact, and performance-based equity distribution, focused on key talent retention and value preservation approaching liquidity events.

Retention and Protection Mechanisms

Vesting framework

This involves a comprehensive four- to five-year vesting schedule with a one-year cliff period, featuring monthly or quarterly accrual post-cliff, strategic acceleration provisions for M&A and IPO scenarios, as well as performance-based vesting criteria linked to both company and individual achievements.

Protection features

These include robust company repurchase rights triggered by departure events, with differentiated valuation mechanisms for unvested shares (at cost) and vested shares (based on departure circumstances), complemented by comprehensive non-compete provisions, full-time commitment requirements, and IP protection measures.

Taxation Structure

Exercise taxation

Tax base is calculated as FMV minus exercise price, subject to progressive rates from 3%–45%, incorporating strategic timing considerations for exercise and disposal, with geographic variations offering potential tax advantages based on local jurisdiction policies.

Capital gains treatment

A standard capital gains rate of 20% applies with an alternative rate of up to 35%, featuring regional variations based on economic zone benefits, municipal regulations and special region provisions, supported by systematic tax optimisation strategies and professional advisory guidance.

Strategic Implementation

Value optimisation

This involves industry-aligned allocation ranges with market-competitive individual grants, incorporating performance linkage mechanisms and regular value assessment, and supported by systematic review processes and adjustment capabilities to maintain competitive positioning.

Risk management

This involves comprehensive dilution control mechanisms integrated with clear documentation requirements, regular compliance monitoring and stakeholder protection measures, balanced with flexibility for market dynamics and company growth requirements.

Integration Framework

Corporate alignment

This involves strategic alignment between equity compensation and corporate objectives, supporting talent acquisition and retention, performance motivation and value creation, while enabling sustainable growth and stakeholder value enhancement.

Governance structure

This is a robust governance framework featuring regular review mechanisms, transparent communication protocols and professional advisory support, ensuring consistent compliance management and effective programme administration.

Implementation Considerations

Practical execution

A systematic implementation approach combines clear communication strategies, regular performance assessment, documented review processes and flexible adjustment mechanisms, supported by professional advisory services and stakeholder engagement.

Market context

The framework reflects the evolution of Chinese equity compensation practices, demonstrating a sophisticated approach to talent retention while balancing international standards with local market requirements, regulatory compliance and stakeholder interests.

Exit Strategies and Shareholder Rights Framework: Core Exit Mechanisms

Drag-along rights

A comprehensive majority investor mechanism enables forced sale participation across all shareholders, providing transaction completion assurance and control premium preservation, while eliminating minority blocking positions and establishing clean exit pathways for trade sales, liquidity events and strategic transactions.

Tag-along/co-sale rights

A robust investor protection framework ensures equitable exit opportunities through guaranteed participation in founder-initiated sales, maintaining transaction term parity and proportional participation, while preventing discriminatory conditions and mitigating valuation disparities across shareholder classes.

Redemption rights

A structured investor exit guarantee system is activated by specific milestones or trigger events, including failed IPO attempts, missed strategic objectives or extended investment periods, and material breaches of representations or covenants, executed through company-funded redemption, founder-led share buybacks or predetermined valuation formulas.

Value Protection Structure

Liquidation preferences

A sophisticated priority distribution framework provides preferred shareholder protection through multiple structures (participating, non-participating, capped preferences), establishing clear hierarchical recovery mechanisms for investor capital protection and downside risk mitigation.

Transfer Restriction Mechanisms

Founder transfer constraints

Comprehensive restrictive transfer protocols require investor consent, strategic holding periods and structured approval processes, balanced with company growth requirements and market dynamics.

Right of first refusal

This involves a founders’ share transfer process that incorporates investor right of first refusal (ROFR), mandatory offer notifications and opportunity matching for third-party terms, supported by structured transfer approval protocols and stakeholder protection measures.

Investor Transfer Guidelines

The nuanced transfer framework incorporates competitive restrictions, prohibited sales to predefined competitors and strategic market protection measures, while maintaining appropriate transaction flexibility.

Implementation Framework

Documentation requirements

The comprehensive legal framework incorporates detailed shareholders’ agreement provisions, clear trigger event definitions, structured valuation methodologies and systematic process execution protocols, supported by professional advisory guidance.

Execution mechanisms

Standardised implementation procedures feature clear notification requirements, defined response timelines, transparent pricing mechanisms and established dispute resolution protocols, ensuring consistent and efficient execution.

Strategic Considerations

Value optimisation

This involves a systematic approach to transaction timing, valuation maximisation and stakeholder alignment, incorporating market condition assessments and strategic positioning to enhance exit outcomes.

Risk management

The comprehensive protection framework balances minority shareholder rights with majority control, ensuring fair treatment across shareholder classes while maintaining flexibility for market dynamics and growth requirements.

Practical Application

Exit preparation

The strategic preparation framework combines timing assessment, stakeholder communication, documentation readiness and process optimisation, supported by professional advisory services and systematic review procedures.

Transaction execution

A structured execution approach incorporates clear approval processes, transparent communication protocols and comprehensive compliance management, ensuring efficient and equitable transaction completion.

Traditional Market Foundation

A-Share market position

The A-Share market stands as China’s traditional cornerstone for corporate exits, offering domestic prestige combined with streamlined regulatory navigation. This primary route leverages established domestic investor relationships and regulatory familiarity, providing natural advantages in market understanding and compliance efficiency. Companies benefit from cultural alignment and simplified communication channels, particularly valuable for enterprises with strong domestic market presence.

Regulatory environment

The China Securities Regulatory Commission’s (CSRC) oversight has evolved into a sophisticated framework emphasising stringent listing requirements and enhanced financial scrutiny. Modern regulatory focus centres on financial transparency, corporate governance excellence and business model sustainability, while maintaining robust anti-speculation measures. This environment demands thorough operational history validation and precise financial performance documentation, creating a comprehensive but navigable regulatory landscape.

Market Dynamics

Contemporary challenges

Market conditions present complex challenges through macroeconomic uncertainties and sector-specific variations. The listing environment features extended review timelines and heightened rejection risks, requiring sophisticated preparation strategies. Companies must navigate valuation volatility while maintaining flexibility in market access timing and implementation approaches.

Strategic response

Successful navigation requires balanced preparation incorporating financial readiness, governance enhancement and stakeholder communication. Companies must maintain adaptable timelines while ensuring comprehensive documentation and professional advisory support, enabling responsive adjustment to market conditions while preserving strategic objectives.

International Listing Framework

Hong Kong Exchange (HKEX) pathway

HKEX offers a strategic hybrid platform combining international market access with regional proximity advantages. This route provides familiar regulatory frameworks aligned with international standards while maintaining strong mainland connections. Companies benefit from enhanced global visibility while leveraging existing cultural and operational synergies.

NASDAQ positioning

NASDAQ listings deliver advanced international market integration and sophisticated infrastructure access. This pathway particularly suits technology-driven enterprises seeking global ecosystem integration and institutional investor exposure. Companies gain access to deep liquidity pools and comprehensive research coverage while meeting elevated international standards.

Implementation Strategy

Location selection

Venue selection demands systematic evaluation of market depth, regulatory requirements and investor base characteristics. Analysis must balance quantitative metrics with qualitative factors including peer group alignment and index inclusion potential, while maintaining focus on long-term strategic objectives.

Preparation framework

Successful execution requires meticulous financial preparation, governance enhancement and compliance readiness. Companies must develop comprehensive stakeholder communication strategies while maintaining flexibility for evolving market conditions and regulatory requirements.

Risk Management

Regulatory navigation

Effective risk management combines multi-jurisdictional compliance expertise with systematic monitoring of market conditions. Companies must maintain robust contingency planning while ensuring responsive adaptation to regulatory developments and market sentiment changes.

Market timing

Strategic timing optimisation requires balanced consideration of market conditions, valuation environments and investor sentiment. Companies must maintain preparation readiness while preserving flexibility to capture optimal market windows.

Future Outlook

Market evolution

Capital markets continue advancing through regulatory modernisation and international integration enhancement. Evolution encompasses increasing sophistication in trading mechanisms and valuation methodologies while maintaining focus on market stability and investor protection.

Strategic adaptation

Forward-looking planning must incorporate emerging opportunities and regulatory changes while maintaining core strategic alignment. Companies must balance traditional market strengths with international opportunities while ensuring sustainable competitive positioning.

Secondary Market Trading and Liquidity Mechanisms in the Chinese Venture Ecosystem

Market liquidity landscape and emerging secondary market dynamics

The Chinese venture ecosystem faces significant liquidity challenges stemming from traditional exit limitations, including extended IPO timelines, persistent regulatory uncertainties and prolonged investment holding periods. These challenges directly impact various stakeholders’ needs, particularly in investor capital optimisation, employee equity monetisation and portfolio management flexibility. The evolving landscape necessitates innovative approaches to address these fundamental market constraints.

Structured liquidity mechanisms and secondary trading frameworks

To address market inefficiencies, emerging liquidity solutions have developed through structured approaches encompassing controlled secondary transactions, investor-to-investor transfers and company-facilitated trading platforms. These solutions are implemented through carefully regulated transfer mechanisms, transparent valuation processes and comprehensive compliance protocols, ensuring market integrity while facilitating necessary liquidity.

Regulatory and structural barriers in secondary market development

The development of robust secondary markets faces substantial impediments, including limited market infrastructure, strict transfer restrictions and complex compliance requirements. These challenges are compounded by valuation complexities, characterised by inconsistent pricing mechanisms, significant information asymmetry and limited market transparency, creating barriers to efficient secondary market operations.

Legal and governance framework

Successful secondary market operations require well-structured legal parameters, including comprehensive shareholders’ agreements, clear transfer restriction provisions and detailed valuation methodologies. These are supported by robust governance mechanisms incorporating board approval processes, ROFR protocols and investor consent requirements, ensuring orderly market function while protecting stakeholder interests.

Future outlook

The Chinese venture ecosystem’s secondary market is poised for continued evolution, with developments expected in trading mechanisms, more sophisticated liquidity solutions and increased regulatory clarity. These advancements will likely facilitate more efficient capital recycling and improved market functionality, benefiting all ecosystem participants.

Regulatory Foundation

Legal ecosystem integration

The Chinese equity securities framework operates within an intricate regulatory ecosystem, integrating multiple legal domains including corporate law, securities regulations, foreign investment frameworks, employment legislation and tax compliance mechanisms. This multidimensional legal structure requires sophisticated navigation of intersecting regulatory requirements while maintaining operational efficiency and strategic flexibility in transaction execution.

Regulatory oversight structure

Primary regulatory oversight combines the co-ordinated efforts of key authorities including the CSRC, the Ministry of Commerce (MOFCOM), SAFE and the National Tax Administration. This integrated regulatory approach demands comprehensive cross-jurisdictional compliance while maintaining holistic regulatory perspective across all transaction dimensions.

Transaction Framework

Structural implementation

Transaction execution requires navigation of sophisticated compliance requirements through adaptable offering structures and flexible equity distribution mechanisms. This framework incorporates detailed documentation protocols while implementing tax efficiency strategies through optimised equity allocation and transfer pricing mechanisms, ensuring minimised tax burden within regulatory constraints.

Operational framework

Practical implementation encompasses systematic management of regulatory approval processes, including detailed documentation requirements and complex approval hierarchies. This operational structure requires proactive regulatory navigation supported by comprehensive due diligence and adaptive compliance strategies, ensuring sustainable transaction execution while maintaining regulatory alignment.

Legal Architecture

Corporate governance framework

Governance structures incorporate detailed shareholders’ agreement provisions covering comprehensive equity offering terms, transfer restriction protocols and rights definition. Articles of association provide foundational support through detailed equity issuance guidelines, governance structure specifications and robust investor protection mechanisms, ensuring comprehensive stakeholder protection.

Securities regulation compliance

Securities compliance demands comprehensive information transparency through detailed financial reporting and investor protection mechanisms. This framework requires systematic documentation processes, precise regulatory submissions and comprehensive compliance verification, maintaining regulatory alignment while preserving transaction efficiency.

International Investment Integration

Cross-border transaction management

International investment frameworks require sophisticated navigation of foreign investment review processes, capital control regulations and cross-border transfer restrictions. This structure demands adaptive investment mechanisms and comprehensive regulatory navigation strategies, ensuring successful cross-border transaction execution while maintaining compliance integrity.

Future Development Trajectory

Evolution dynamics

Market evolution continues through increasing regulatory sophistication and enhanced compliance frameworks. This development encompasses more integrated regulatory approaches and continued market evolution, requiring adaptive strategic responses and sophisticated compliance mechanisms.

Strategic adaptation

Forward-looking planning must incorporate emerging regulatory trends and evolving market requirements while maintaining operational efficiency. This approach enables sustainable transaction execution through adaptive compliance strategies and sophisticated structural solutions.

Foreign VC Investment: Chinese Regulatory Framework

The dynamic investment environment

The Chinese foreign investment landscape operates within an evolving regulatory ecosystem characterised by multidimensional restriction mechanisms encompassing foreign direct investment (FDI) regulations, currency controls, sector-specific limitations and national security considerations. This adaptive framework demonstrates continuous policy refinement reflecting geopolitical sensitivities and strategic economic alignment, requiring sophisticated navigation of dynamic regulatory requirements. The system maintains a systematic balance between investment attraction and market protection through comprehensive control mechanisms while enabling sustainable market development trajectories aligned with national strategic objectives.

Strategic Regulatory Architecture

The regulatory structure implements sophisticated oversight through integrated control mechanisms and strategic sector development initiatives. This comprehensive framework enables measured economic openness while preserving critical national interests through systematic monitoring and adaptive policy implementation. The architecture demonstrates increasing sophistication in balancing foreign participation with domestic market development, supported by enhanced compliance mechanisms and strategic sector alignment protocols.

FDI Framework

Negative list mechanism

The negative list system provides comprehensive investment restriction frameworks through precise industry categorisation and dynamic restriction protocols. Annual regulatory updates ensure alignment with strategic economic objectives while maintaining systematic sector protection mechanisms. This structure enables clear operational guidance for foreign investors while preserving flexibility for policy adjustment and strategic sector development, supported by sophisticated compliance verification systems and detailed implementation protocols.

Industry classification framework

Prohibited sectors

Absolute restriction domains encompass strategically sensitive sectors including news media, publishing, cultural production and specific financial services. This framework maintains cultural integrity and information ecosystem control while preserving core national sovereignty interests through comprehensive restriction mechanisms. The system implements sophisticated monitoring protocols and systematic compliance verification while maintaining clear boundaries for foreign participation across restricted sectors.

Restricted industries

Controlled foreign participation frameworks govern strategic sectors including telecommunications, education and healthcare through sophisticated investment constraint mechanisms. These frameworks integrate detailed equity ownership caps, mandatory approval processes and comprehensive qualification requirements, while maintaining systematic oversight of foreign participation. The structure enables measured market access while preserving regulatory control through integrated monitoring systems and adaptive compliance requirements.

Encouraged sectors

Strategic investment promotion focuses on targeted sector development through sophisticated incentive mechanisms including tax optimisation strategies and streamlined approval processes. This framework provides preferential policy access and simplified regulatory navigation while maintaining alignment with national development objectives. The system implements comprehensive support mechanisms while ensuring appropriate oversight and compliance verification through integrated monitoring protocols.

Currency Control Architecture

SAFE regulatory framework

SAFE maintains comprehensive capital flow management through sophisticated cross-border transaction governance. This integrated system combines mandatory investment registration, detailed reporting protocols and systematic compliance verification, while enabling controlled capital movement. The framework implements comprehensive monitoring mechanisms while maintaining necessary flexibility for legitimate investment operations through sophisticated control protocols.

Capital movement mechanisms

The capital movement structure implements sophisticated regulatory controls through integrated approval processes and systematic compliance verification. This framework enables controlled capital flows while maintaining market stability through comprehensive monitoring systems and adaptive control mechanisms. The structure demonstrates increasing sophistication in balancing transaction efficiency with regulatory oversight, supported by enhanced verification protocols and strategic risk management systems.

Free Trade Zone Innovation

Strategic pilot programmes

Breakthrough regulatory approaches in pilot free trade zones demonstrate measured market opening through controlled foreign participation in strategic sectors. These programmes implement systematic innovation within controlled regulatory frameworks while maintaining comprehensive oversight mechanisms. The structure enables targeted experimentation with regulatory reforms while preserving strategic control through integrated monitoring systems and adaptive compliance requirements.

Innovation ecosystem development

Key pilot regions including Beijing, Shanghai, Guangdong and Hainan Free Trade Zones provide comprehensive innovation ecosystems through systematic policy experimentation and gradual regulatory liberalisation. These controlled innovation corridors enable measured testing of regulatory reforms while maintaining strategic oversight through sophisticated monitoring protocols and integrated compliance systems. The framework demonstrates increasing sophistication in balancing innovation promotion with regulatory control through enhanced verification mechanisms and strategic alignment protocols.

In a landmark policy shift for 2024–2025, China significantly opened its gene therapy sector to foreign investment, marking a strategic departure from its traditionally prohibited stance. Through a carefully structured pilot programme in designated free trade zones, foreign enterprises can now invest in and develop technologies across key areas including human stem cell research, gene therapy, genetic diagnosis and cell therapy applications. This policy change not only demonstrates China’s commitment to advancing its biotechnology sector but also creates unprecedented opportunities for international collaboration and knowledge transfer.

While maintaining necessary regulatory oversight and compliance requirements, this opening is expected to accelerate China’s development in advanced medical treatments by attracting substantial foreign expertise and capital. The move reflects China’s broader strategy of strengthening its position in the global biotechnology landscape while ensuring controlled and regulated market access for foreign participants in this sensitive healthcare sector.

2026 Company Law Enforcement: Second Year Implementation

The new Company Law, effective 1 July 2024, entered its second year of enforcement in mid-2025. As we move through early 2026, market supervision authorities continue to actively enforce the requirement that shareholders complete capital contributions within five years, placing sustained pressure on start-ups with inflated registered capital or extended contribution schedules.

In practice, many portfolio companies have been forced into capital reductions, down-round financings, or emergency bridge funding. Enforcement approaches continue varying by jurisdiction: cities such as Shanghai and Hangzhou maintain stricter interpretations, calculating the five-year period from amendment registration dates rather than permitting the national grace period extending to 30 June 2032.

Article 88’s supplementary liability for equity transferors initially chilled secondary transactions through late 2024. The Supreme People’s Court subsequently clarified that Article 88 does not apply retroactively to equity transfers completed before 1 July 2024, partially easing market concerns. However, all transactions since 1 July 2024 remain subject to this provision, requiring careful structuring and due diligence as we progress through 2026.

Director liability has expanded materially under the new law. Directors – particularly those appointed by PE/VC funds – now face potential personal exposure if they fail to issue formal capital call demands to defaulting shareholders. As a result, directors and officers (D&O) insurance adoption has surged, and many companies have streamlined governance structures by replacing supervisory boards with audit committees. This trend is expected to continue through 2026 as governance practices adapt to the new legal framework.

Data Security and Cybersecurity Compliance in 2026

Transactions increasingly incorporate comprehensive cybersecurity audits, data mapping and cross-border data transfer assessments as we move through 2026, driven by:

  • the Network Data Security Management Regulation, effective 1 January 2025, which transformed data governance from policy guidance into enforceable obligations and has now been in force for over one year; and
  • the amended Cybersecurity Law, adopted in October 2025 and effective 1 January 2026, which increased penalties and expanded extraterritorial reach – now in its initial enforcement phase.

As these frameworks mature through 2026, compliance requirements are becoming increasingly well defined, but enforcement is also becoming more rigorous. PE/VC investors must conduct thorough data compliance due diligence on all technology-sector targets and ensure that portfolio companies maintain robust data governance frameworks.

Zhong Lun Law Firm

10/11/16/17F
Two IFC
8 Century Avenue
Pudong New Area
Shanghai 200120
China

+86 21 6061 3155

+86 21 6061 3555

zlmarketing@zhonglun.com www.zhonglun.com
Author Business Card

Trends and Developments


Authors



Zhong Lun Law Firm was established in 1993, and is a pioneering partnership law firm in China. Through decades of strategic growth and unwavering commitment to excellence, the firm has emerged as a pre-eminent full-service law firm. With nearly 400 equity partners and a robust team of over 2,200 professionals, Zhong Lun represents the pinnacle of legal expertise and institutional capability. As one of the first Chinese law firms to specialise in private equity, Zhong Lun has developed unparalleled insights and deep-rooted expertise in this complex domain. Its practice comprehensively addresses the entire life cycle of private fund operations. By combining meticulous legal acumen with strategic foresight, the firm has consistently positioned itself as a leading legal service provider in China’s dynamic private equity landscape. Its sustained excellence has been internationally recognised, with Chambers Global repeatedly ranking Zhong Lun in Band 1 for Private Equity – a testament to the firm’s exceptional performance and industry leadership.

Trends and Developments in China’s Private Equity Sector: a Legal and Regulatory Perspective

China’s private equity (PE) and venture capital (VC) markets entered 2026 with cautious optimism following a multi-year period of adjustment. While market fundamentals showed signs of stabilisation through 2025, evolving USA–China tensions, enforcement of the Company Law (now in its second year) and shifting judicial approaches to redemption rights continue to reshape investment strategies, deal structuring and exit planning into 2026.

Market Dynamics, Geopolitics and Exits

Market recovery and current conditions

China’s PE/VC sector demonstrated tentative recovery throughout 2025 and into early 2026. Exit activity improved unevenly, with recovery concentrated in strategic sales and selective Hong Kong listings rather than broad-based public market exits. M&A exits gained significant momentum, supported by regulatory reforms and investor pragmatism in response to persistent IPO constraints.

By early 2026, the bifurcated exit landscape has become entrenched: M&A transactions and Hong Kong listings continue to gain traction while A-share IPOs remain structurally constrained. This dynamic is forcing funds to maintain recalibrated exit expectations and extended portfolio timelines established during 2024–2025.

Fundraising conditions remain challenging, with Mainland China-focused PE and VC funds experiencing subdued capital raising through late 2025. However, strategic domestic investments have driven M&A transaction value growth, with first-half 2025 figures showing a 45% year-over-year surge in deal value.

Geopolitical Decoupling and Cross-Border Investment Controls

USA–China geopolitical tensions have intensified significantly, fundamentally reshaping cross-border investment flows and compliance obligations as we move through 2026.

The US Treasury’s Outbound Investment Security Program (OISP) has been operational since 2 January 2025, implementing Executive Order 14105. The regime prohibits or requires notification of US investments involving Chinese semiconductors, quantum technologies and certain artificial intelligence (AI) systems. Throughout 2025, enforcement focused on notification compliance, but Treasury has signalled increasingly strict enforcement ahead.

More significantly, the Fiscal Year 2026 National Defense Authorization Act, signed in December 2025, codified and substantially expanded outbound screening requirements under the Comprehensive Outbound Investment National Security (COINS) Act. This grants Treasury enhanced enforcement authority and mandates further rulemaking. Implementing regulations, expected by late 2026 or 2027, are widely anticipated to:

  • expand covered sectors beyond the current semiconductor, quantum and AI categories – potentially capturing advanced manufacturing, synthetic biology and additional AI applications;
  • lower de minimis thresholds for notification requirements; and
  • create stricter due diligence and compliance obligations for US persons and covered entities.

Market participants should assume that the current framework represents a regulatory floor, not a ceiling. The trajectory clearly points towards more extensive restrictions on US capital flows into Chinese technology sectors.

Simultaneously, Committee on Foreign Investment in the United States (CFIUS) scrutiny has intensified for investments from “countries of concern”, while requirements have eased for allied jurisdictions. This asymmetry reflects deliberate US policy to construct differentiated capital flow regimes that channel investment towards allied ecosystems while restricting China-bound flows in sensitive sectors.

US-origin capital flows into Chinese technology sectors continued declining through 2025 and into early 2026. Major global firms maintain strict operational and governance firewalls between China and non-China platforms following earlier structural separations.

Chinese companies and their investors now face the dual challenge of complying both with China’s data localisation and cybersecurity requirements and with US national security mandates – significantly increasing transaction complexity and compliance costs as we progress through 2026.

Technology Investment Despite Constraints

Despite geopolitical headwinds, technology investment rebounded through 2025. President Xi’s 2026 New Year address highlighted that AI large models accelerated rapidly and domestically developed chips achieved new breakthroughs in 2025, reinforcing continued policy support for hard technology sectors into 2026.

China announced large-scale semiconductor and AI funding initiatives throughout 2025, with the National AI Industry Investment Fund launched in January 2025 at USD8.2 billion representing just one component of broader strategic investment estimated at tens of billions of US dollars. Despite US restrictions, China’s semiconductor firms posted substantial profit growth in 2025 amidst the AI boom and tech self-reliance drive, with this momentum expected to continue into 2026.

Life sciences and biotechnology continued to attract capital due to streamlined regulatory pathways and policy prioritisation, benefiting additionally from a dramatic global biotech resurgence through 2025. Global pharmaceutical M&A activity surged with deal values climbing substantially as Big Pharma confronted a looming USD170 billion patent cliff, while biotech equities posted their strongest performance since the COVID-19 pandemic and PE capital returned to the sector after a prolonged funding chill. The sector has also demonstrated notable structural creativity, with innovative “newco” models gaining traction – arrangements combining licensing agreements with equity stakes in newly formed entities, allowing pharmaceutical companies and biotech investors to share risk while maintaining flexibility around asset development and commercialisation. This global momentum – driven by surging business development deals, creative deal structures, reviving secondary markets and renewed PE deployment – creates premium exit opportunities for Chinese biotech investors through both strategic acquisitions and international capital markets, positioning life sciences as one of the few sectors where Chinese PE/VC can access both domestic and cross-border liquidity despite broader geopolitical constraints.

Real estate and infrastructure remained subdued amidst tighter oversight of leverage and financing structures – a dynamic that is expected to persist through 2026.

Exit Strategies: Three Divergent Paths

Exit strategy 1: M&A takes the lead

Facing persistent IPO uncertainty and historically low judicial recovery rates on share repurchases, PE/VC investors increasingly favoured M&A exits throughout 2025, and this trend is accelerating into 2026.

Policy support proved decisive. Key measures included:

  • the China Securities Regulatory Commission’s (CSRC) June 2024 “Eight Measures” supporting M&A and restructuring, particularly for technology-oriented listed companies;
  • September 2024 reforms easing certain cross-border M&A approval bottlenecks; and
  • the May 2025 revised Asset Reorganization Measures (CSRC Order No 230), introducing simplified review procedures and a “reverse linkage” mechanism aligning PE fund investment terms with lock-up requirements for restructuring-acquired shares.

These reforms have streamlined M&A execution and enhanced predictability. Compared with IPO exits, M&A transactions offer clear advantages: significantly shorter execution timelines (often measured in months rather than years), flexible pricing mechanisms including earn-outs and instalment payments, and reduced exposure to secondary market restrictions on share reductions and disclosure requirements.

The LaNova Medicines case: financial investor windfall through strategic M&A

The July 2025 acquisition of LaNova Medicines by Hong Kong-listed Sino Biopharmaceutical exemplifies how strategic M&A has emerged as the premier exit route for life sciences PE/VC investors. The transaction valued LaNova at approximately USD951 million, representing one of the largest pharmaceutical deals in the Asia-Pacific region in 2025. From the financial investors’ perspective, the transaction delivered exceptional returns and strategic validation.

Rapid value creation

LaNova had raised approximately USD200 million through multiple funding rounds from PE/VC investors. The USD951 million acquisition represented a substantial multiple on invested capital, achieved within a relatively compressed timeframe despite challenging market conditions.

Strategic licensing as a driver of value

Financial investors benefited enormously from LaNova’s strategic licensing deals with Western pharmaceutical giants, which de-risked the technology platform and validated commercial potential well before exit. AstraZeneca licensed LM-305, a G-protein targeting ADC in 2023. More significantly, in 2024, Merck & Co secured global rights to LM-299, an anti-PD-1/VEGF bispecific antibody. These licensing transactions transformed LaNova from a clinical-stage biotech into a proven innovation platform with blue-chip validation, directly driving acquisition valuation.

M&A advantages over IPOs

The strategic acquisition route provided PE/VC investors with several critical advantages over the alternative IPO path.

  • Certainty and speed: the transaction closed within approximately 30 business days from announcement, providing liquidity far faster than the protracted IPO approval process that stalled numerous biotech listings through 2025.
  • Full liquidity: Sino Biopharmaceutical acquired 100% of LaNova (having previously held 4.91% from November 2024), enabling complete portfolio exits without the lock-up periods, share reduction restrictions, and market liquidity constraints that plague post-IPO exits in both A-share and Hong Kong markets.
  • Valuation protection: the negotiated acquisition price of USD951million (approximately USD500.9 million net of cash) protected investors from the valuation volatility and post-IPO price declines that characterised biotech public offerings through 2024–2025.
  • Regulatory simplicity: unlike IPO exits requiring CSRC filing notices, extended reviews and ongoing public company compliance, the M&A transaction required only standard merger control and foreign investment approvals – a far less burdensome process.

Strategic buyer rationale

Sino Biopharmaceutical’s acquisition was driven by the desire to strengthen R&D capabilities and enhance competitiveness in oncology – precisely the type of strategic rationale that supports premium valuations. LaNova’s robust pipeline (two registration-stage projects, six Phase I/II trials, and over ten pre-clinical programmes) and proven platform technology justified the near-billion-dollar valuation despite the absence of marketed products.

Investor takeaways

For PE/VC investors in Chinese life sciences companies, the LaNova transaction reinforces several strategic lessons:

  • early-stage licensing partnerships with multinational pharmaceutical companies serve dual purposes – they provide validation and non-dilutive capital while creating option value that strategic acquirers will pay premiums to control;
  • platform technology companies with multiple pipeline assets command significantly higher M&A valuations than single-asset biotechs, even in clinical stages;
  • strategic M&A exits can deliver superior risk-adjusted returns compared to IPO routes, particularly when licensing deals have already established fair market valuation benchmarks; and
  • Chinese biotech assets remain highly attractive to domestic strategic acquirers despite broader market headwinds, as companies such as Sino Biopharmaceutical pursue innovation-driven growth strategies.

The momentum built through 2025 is expected to continue into 2026, with M&A likely remaining the primary exit route for PE/VC investors in the absence of significant changes to the IPO approval environment. Strategic acquisitions such as the LaNova transaction demonstrate that, despite challenging market conditions, well-positioned portfolio companies with validated technology platforms and strong pipelines can achieve substantial exits that deliver exceptional returns to financial investors.

Exit strategy 2: A-Share IPOs remain constrained

The domestic A-share IPO market remained under sustained pressure throughout 2025 and into early 2026. In 2024, A-share IPOs raised only approximately CNY67.35 billion, marking one of the weakest years in recent history. Through 2025, more than 70 issuers withdrew IPO applications amidst heightened regulatory scrutiny and valuation concerns.

By early 2026, the CSRC’s IPO review queue has declined to approximately 200–230 projects, down from prior peaks but still reflecting a cautious approval environment. For many PE/VC-backed companies, the prolonged review cycle and uncertain outcomes have reinforced the structural shift towards M&A exits and overseas listings, with this dynamic expected to persist in the absence of fundamental policy changes.

Exit strategy 3: Hong Kong dominates, but variable interest entity (VIE) structures face headwinds

In contrast to the Mainland market, Hong Kong re-emerged as the primary overseas listing venue for Chinese enterprises through 2025 and into 2026. From January 2024 through mid-2025, roughly 195 issuers obtained CSRC filing notices for overseas listings. Hong Kong captured the clear majority, with filing acceptance rates and processing times significantly outperforming US listings. Among H1 2025 filing recipients, approximately three quarters selected Hong Kong; among accepted submissions, Hong Kong accounted for over 90%.

A-to-H listings gained traction. Approximately 35 A-share companies announced H-share plans through 2025, benefiting from expedited CSRC filing timelines averaging about four months – signalling clear regulatory support for dual listings. This momentum is expected to continue into 2026.

By contrast, VIE-structured issuers faced heightened scrutiny through 2025 and into early 2026. VIE applicants continue to experience time-consuming and difficult paths to obtaining CSRC filing notices, reflecting ongoing regulatory concerns over compliance, foreign investment restrictions and practical enforceability. While the CSRC has not formally prohibited VIE structures, the filing process has become a de facto filter:

  • sector sensitivity matters – VIE applicants in data-intensive, media or education sectors face substantially higher rejection risks than those in consumer or industrial businesses;
  • legacy versus new structures – companies with long-established VIE arrangements and clean compliance histories fare significantly better than recent formations; and
  • contractual robustness – regulators increasingly probe the enforceability of VIE control agreements, particularly where WFOE-to-VIE payment flows raise transfer pricing or tax concerns.

This cautious regulatory approach to VIE structures is expected to persist through 2026, creating continued challenges for companies seeking overseas listings via this structure.

Legal and Regulatory Developments

Company Law enforcement: second year of implementation

The new Company Law, effective 1 July 2024, completed its first full year of enforcement through mid-2025 and entered its second year in mid-2025. As we move through early 2026, market supervision authorities continue to actively enforce the requirement that shareholders complete capital contributions within five years, placing sustained pressure on start-ups with inflated registered capital or extended contribution schedules.

In practice, many portfolio companies have been forced into capital reductions, down-round financings or emergency bridge funding. Enforcement approaches continue to vary by jurisdiction: cities such as Shanghai and Hangzhou maintain stricter interpretations, calculating the five-year period from amendment registration dates rather than permitting the national grace period extending to 30 June 2032.

Article 88’s supplementary liability for equity transferors initially chilled secondary transactions through late 2024. The Supreme People’s Court subsequently clarified that Article 88 does not apply retroactively to equity transfers completed before 1 July 2024, partially easing market concerns. However, all transactions since 1 July 2024 remain subject to this provision, requiring careful structuring and due diligence as we progress through 2026.

Director liability has expanded materially under the new law. Directors – particularly those appointed by PE/VC funds – now face potential personal exposure if they fail to issue formal capital call demands to defaulting shareholders. As a result, directors and officers (D&O) insurance adoption has surged, and many companies have streamlined governance structures by replacing supervisory boards with audit committees. This trend is expected to continue through 2026 as governance practices adapt to the new legal framework.

Data Security and Cybersecurity Compliance

Transactions increasingly incorporate comprehensive cybersecurity audits, data mapping and cross-border data transfer assessments as we move through 2026, driven by:

  • the Network Data Security Management Regulation, effective 1 January 2025, which transformed data governance from policy guidance into enforceable obligations and has now been in force for over one year; and
  • the amended Cybersecurity Law, adopted in October 2025 and effective 1 January 2026, which increased penalties and expanded extraterritorial reach – now in its initial enforcement phase.

As these frameworks mature through 2026, compliance requirements are becoming increasingly well defined, but enforcement is also becoming more rigorous. PE/VC investors must conduct thorough data compliance due diligence on all technology-sector targets and ensure that portfolio companies maintain robust data governance frameworks.

AMAC Compliance and Private Fund Regulation

The Asset Management Association of China (AMAC) has further tightened private fund manager registration and ongoing compliance requirements through 2025 and into 2026. Managers increasingly face demands for comprehensive internal control audits, independent legal opinions, and enhanced disclosure of fund structures and capital sources.

Regulatory enforcement has accelerated through data-driven supervision, prompting PE firms to deploy AI-assisted compliance systems to monitor trading behaviour, related-party transactions and capital movements. This trend towards technology-enabled regulatory compliance is expected to intensify through 2026 as regulators expand their supervisory capabilities and data requirements.

Redemption Rights: the Six-Month Rule and Ongoing Uncertainty

In December 2025, a Supreme People’s Court justice publicly stated that, where PE/VC agreements do not specify an exercise period for redemption rights or put options, the “reasonable period” should generally be six months from the triggering event, after which the right may be deemed waived.

This position echoed earlier commentary in the People’s Court Daily but stopped short of a formal judicial interpretation. The guidance triggered intense debate that continues into early 2026. Supporters argue that it enhances transactional certainty and corporate stability; critics warn that it could incentivise premature redemptions, exacerbating liquidity stress at portfolio companies.

Judicial practice remains inconsistent as we move through early 2026. Notably, a Beijing court decision in 2025 explicitly declined to adopt the six-month rule, emphasising that such commentary does not constitute binding law. This creates ongoing uncertainty for market participants regarding the practical enforceability and timing requirements for redemption rights.

Despite this uncertainty, redemption rights remain prevalent – approximately 90% of PE/VC transactions include them, and around two thirds impose joint personal liability on founders. Enforcement has driven a surge in litigation, often accompanied by asset preservation orders, travel restrictions, and credit sanctions against founders.

In response, investors are increasingly adopting precise contractual drafting to define:

  • specific trigger events with objective criteria;
  • detailed notice procedures and timelines;
  • explicit exercise periods to avoid default application of the six-month standard; and
  • clear consequences for failure to exercise within specified periods.

This trend towards more detailed redemption provisions is expected to continue through 2026 as market participants seek contractual clarity in the absence of definitive judicial guidance.

Looking Ahead: Key Themes for 2026

As China’s PE/VC sector progresses through 2026, several key themes are likely to shape market dynamics.

Continued exit channel bifurcation

M&A and Hong Kong listings will likely remain the primary exit routes, with A-share IPOs recovering only gradually in the absence of fundamental policy shifts. Investors should maintain diversified exit strategies and realistic timelines.

Escalating USA–China investment restrictions

The COINS Act’s implementation will likely expand prohibited and notifiable transaction categories through 2026–2027. Cross-border investors must build robust compliance frameworks and scenario plans for additional restrictions.

Technology sector resilience

Despite geopolitical headwinds, Chinese technology sectors – particularly AI, semiconductors and life sciences – will likely continue attracting domestic capital supported by government policy and self-reliance imperatives.

Regulatory maturation

Company Law enforcement, data security requirements and AMAC oversight will become increasingly settled through 2026 as initial implementation questions are resolved and enforcement patterns become clearer.

Redemption rights evolution

Whether through formal judicial interpretation, regulatory guidance or market practice standardisation, clarity on redemption right exercise periods should improve through 2026, though the path remains uncertain.

The Chinese PE/VC landscape in 2026 requires sophisticated navigation of geopolitical constraints, regulatory complexity and evolving exit channels. Success will depend on flexible strategy, rigorous compliance and realistic expectations calibrated to China’s unique market environment.

Zhong Lun Law Firm

10/11/16/17F
Two IFC
8 Century Avenue
Pudong New Area
Shanghai 200120
China

+86 21 6061 3155

+86 21 6061 3555

zlmarketing@zhonglun.com www.zhonglun.com
Author Business Card

Law and Practice

Authors



Zhong Lun Law Firm was established in 1993, and is a pioneering partnership law firm in China. Through decades of strategic growth and unwavering commitment to excellence, the firm has emerged as a pre-eminent full-service law firm. With nearly 400 equity partners and a robust team of over 2,200 professionals, Zhong Lun represents the pinnacle of legal expertise and institutional capability. As one of the first Chinese law firms to specialise in private equity, Zhong Lun has developed unparalleled insights and deep-rooted expertise in this complex domain. Its practice comprehensively addresses the entire life cycle of private fund operations. By combining meticulous legal acumen with strategic foresight, the firm has consistently positioned itself as a leading legal service provider in China’s dynamic private equity landscape. Its sustained excellence has been internationally recognised, with Chambers Global repeatedly ranking Zhong Lun in Band 1 for Private Equity – a testament to the firm’s exceptional performance and industry leadership.

Trends and Developments

Authors



Zhong Lun Law Firm was established in 1993, and is a pioneering partnership law firm in China. Through decades of strategic growth and unwavering commitment to excellence, the firm has emerged as a pre-eminent full-service law firm. With nearly 400 equity partners and a robust team of over 2,200 professionals, Zhong Lun represents the pinnacle of legal expertise and institutional capability. As one of the first Chinese law firms to specialise in private equity, Zhong Lun has developed unparalleled insights and deep-rooted expertise in this complex domain. Its practice comprehensively addresses the entire life cycle of private fund operations. By combining meticulous legal acumen with strategic foresight, the firm has consistently positioned itself as a leading legal service provider in China’s dynamic private equity landscape. Its sustained excellence has been internationally recognised, with Chambers Global repeatedly ranking Zhong Lun in Band 1 for Private Equity – a testament to the firm’s exceptional performance and industry leadership.

Compare law and practice by selecting locations and topic(s)

{{searchBoxHeader}}

Select Topic(s)

loading ...
{{topic.title}}

Please select at least one chapter and one topic to use the compare functionality.